Summary
Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K report detailing a significant financing event. On September 28, 2010, the company issued $400.0 million in aggregate principal amount of 3.35% convertible senior subordinated notes due in 2015. These notes are unsecured and rank subordinate to senior debt but are senior to other subordinated debt. The issuance was facilitated through a subordinated indenture and a first supplemental indenture with U.S. Bank National Association as trustee. These convertible notes offer investors the potential for equity upside, as they are convertible into VRTX common stock at a conversion rate of 20.4794 shares per $1,000 principal amount, corresponding to an initial conversion price of approximately $48.83 per share. The company retains certain redemption rights under specific conditions, and noteholders have the right to demand repurchase upon certain fundamental changes. This move indicates Vertex's strategy to access capital, potentially to fund its ongoing research and development or other corporate initiatives.
Key Highlights
- 1Issued $400 million in 3.35% convertible senior subordinated notes due 2015.
- 2Notes are unsecured and subordinate to senior debt.
- 3Interest rate of 3.35% per annum, payable semi-annually.
- 4Notes are convertible into VRTX common stock at a conversion rate of 20.4794 shares per $1,000 principal.
- 5Initial conversion price is approximately $48.83 per share.
- 6Vertex has redemption rights under specific conditions (e.g., stock price exceeding 130% of conversion price for 20 days in 30).
- 7Holders can require repurchase upon certain fundamental changes in the company.